Short answer
biote Corp. (BTMD) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026, reported August 5, 2026.
biote Corp. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026, reported August 5, 2026
- Full financial results and management commentary furnished in Exhibit 99.1
- Investor focus: quarterly performance, outlook, and any guidance changes in the accompanying release
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue fell 9.5% to $44.2M, with procedure revenue down 13.9% to $30.3M from the January 2026 voluntary recall
- Gross margin contracted to 65.4% from 71.6% due to higher replacement-product costs and reduced Asteria Health manufacturing efficiency
- Net loss reached $7.4M, or $(0.23) per diluted share, versus $3.9M net income and $0.10 EPS in Q2 2025
- Adjusted EBITDA declined to $5.6M from $15.2M, while margin fell to 12.6% from 31.1%
- Full-year guidance now calls for revenue above $175M and Adjusted EBITDA above $25M, with procedure revenue growth delayed beyond 2026 second-half periods
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other biote Corp. 8-K filings
Get the next BTMD 8-K as it lands
Follow BTMD for push alerts, or ask the research agent what this filing means.